Phase 1/2a Clinical Trials of Bi-1206, a Monoclonal Antibody to Fcγriib, Administered as a Single Agent or in Combination With Rituximab in Subjects With B-Cell Malignancies

Hematological Oncology - United Kingdom
doi 10.1002/hon.206_2631

Related search